TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6282455

Group type: COMPARATOR
Intervention: MACC chemotherapy only (methotrexate, doxorubicin, cyclophosphamide, and lomustine)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: MACC plus levamisole (LMS)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: MACC plus Corynebacterium parvum (CP)
Number of subjects: 109
Study: 31836012

Group type: EXPERIMENTAL
Intervention: Increased first trimester leptin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Increased first trimester resistin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Increased first trimester visfatin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Leptin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Resistin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Visfatin
Number of subjects: 140
Study: 27860068

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 109

Group type: COMPARATOR
Intervention: Sham CPAP (CPAP withdrawal)
Number of subjects: 109
Study: 26163437

Group type: EXPERIMENTAL
Intervention: Cisplatin-chemoradiotherapy (CRT) with weekly cisplatin (30 mg/m(2)/w)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cetuximab-radiotherapy (ERT) with loading dose of 400 mg/m(2) followed by weekly doses of 250 mg/m(2)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cetuximab-radiotherapy (ERT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cisplatin-chemoradiotherapy (CRT)
Number of subjects: 44
Study: 23395639

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon alfa
Number of subjects: 0
Study: 21177284

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP block
Number of subjects: 273

Group type: COMPARATOR
Intervention: Blind IHN block
Number of subjects: 273
Study: 19369376

Group type: EXPERIMENTAL
Intervention: High micronutrient treatment (100% RDA)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Low micronutrient treatment (15% RDA)
Number of subjects: 598

Group type: COMPARATOR
Intervention: n-3 treatments (900 mg alpha-linolenic acid + 100 mg docosahexaenoic acid or 140 mg alpha-linolenic acid)
Number of subjects: 598
Study: 18200994

Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intracuff lidocaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 14762227

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg q.d. a.m.
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg q.d. p.m.
Number of subjects: 697

Group type: COMPARATOR
Intervention: Celecoxib 100 mg b.i.d.
Number of subjects: 697
Study: 11241051

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy (0.074 mg/kg, subcutaneously, 3 times per week)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study: 9510489

Group type: EXPERIMENTAL
Intervention: Dual chamber pacing in VDD mode
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unpaced controls
Number of subjects: 15
Study: 9152782

Group type: EXPERIMENTAL
Intervention: Captopril (37.5 mg daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 2376254

Group type: EXPERIMENTAL
Intervention: Terbutaline via Nebuhaler (250 micrograms/puff)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Salbutamol via Volumatic (100 micrograms/puff)
Number of subjects: 30
Study: 675213

Group type: EXPERIMENTAL
Intervention: fenoterol (1.25 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: reproterol (2.5 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: terbutaline (2.5 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: salbutamol (1.25 mg)
Number of subjects: 37
Study: 30945505

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with medication (Diclofenac Diethylamine Emulgel, 3 times a day for 2 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication group (Diclofenac Diethylamine Emulgel, 3 times a day for 2 weeks)
Number of subjects: 60
Study: 28145128

Group type: EXPERIMENTAL
Intervention: Power Plate (PP) program with small prizes for selection
Number of subjects: 207
Study: 25935840

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 or 4 mg kg(‐1))
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care (neostigmine/glycopyrrolate)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 154
Study: 22890637

Group type: EXPERIMENTAL
Intervention: Clazosentan (intervention from CONSCIOUS‐1 study)
Number of subjects: 97
Study: 21546719

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (vitamin A, vitamin C, vitamin E)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 39
Study: 19018239

Group type: EXPERIMENTAL
Intervention: Direct sirolimus-eluting stent (SES) implantation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Complementary stenting (CS)
Number of subjects: 39
Study: 17517850

Group type: EXPERIMENTAL
Intervention: Tafenoquine (200 mg loading dose daily for 3 days, followed by 200 mg weekly for 6 months)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Tafenoquine
Number of subjects: 490
Study: 14739872

Group type: EXPERIMENTAL
Intervention: Group 1 (least feedback)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Group 2 (intermittent feedback)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Group 3 (more frequent intermittent feedback)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Group 4 (constant feedback)
Number of subjects: 35
Study: 11549646

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 or 120 mg/d)
Number of subjects: 100
Study: 9542478

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 15 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zolmitriptan (all doses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7864934

Group type: EXPERIMENTAL
Intervention: simvastatin 20 mg daily
Number of subjects: 381

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 381
Study: 3212150

Group type: EXPERIMENTAL
Intervention: Amitriptyline (37.5, 70 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Trazodone (100, 200 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Viloxazine (100, 200 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Protriptyline (10, 20 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 29990038

Group type: EXPERIMENTAL
Intervention: CROification algorithm using the CRO feature map with linear SVM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gaussian kernel SVM
Number of subjects: 0
Study: 27995519

Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg subcutaneously every 28 days
Number of subjects: 309

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 309
Study: 25591130

Group type: EXPERIMENTAL
Intervention: Hip strengthening exercise program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Leg strengthening exercise program
Number of subjects: 72
Study: 23340530

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) at 42° C for 120 seconds, applied twice, once a week for 3 weeks.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham group (no radiofrequency energy output)
Number of subjects: 96
Study: 21907499

Group type: EXPERIMENTAL
Intervention: Involuntary medication treatment
Number of subjects: 0
Study: 19401368

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0
Study: 17127797

Group type: EXPERIMENTAL
Intervention: Ethanol dose 1-2 ml (Group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ethanol dose >2 ml (Group B)
Number of subjects: 54
Study: 15262845

Group type: EXPERIMENTAL
Intervention: Sirolimus 3 mg/d
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Sirolimus 5 mg/d
Number of subjects: 136

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 136
Study: 10903230

Group type: EXPERIMENTAL
Intervention: Noninvasive investigation (Group 1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Invasive investigation (Group 2)
Number of subjects: 76
Study: 9076457

Group type: EXPERIMENTAL
Intervention: Mitomycin C instillation (20-week protocol)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Doxorubicin instillation (3-year protocol)
Number of subjects: 419
Study: 8261886

Group type: EXPERIMENTAL
Intervention: Ascorbic acid aerosol device with clinical counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fine particle ascorbic acid device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coarse particle ascorbic acid device
Number of subjects: 0
Study: 2579868

Group type: EXPERIMENTAL
Intervention: Intraduodenal mixed nutrients, proteins, and lipids
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intraduodenal lipids
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intraduodenal sugars
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intraduodenal mixed meal
Number of subjects: 6
Study: 30837195

Group type: EXPERIMENTAL
Intervention: BoNT plus PT (PT‐BoNT arm)
Number of subjects: 26

Group type: COMPARATOR
Intervention: BoNT alone (BoNT arm)
Number of subjects: 26
Study: 30388182

Group type: EXPERIMENTAL
Intervention: Behavior Changing Intervention (BCI)
Number of subjects: 2140

Group type: EXPERIMENTAL
Intervention: Knowledge related module
Number of subjects: 2140

Group type: EXPERIMENTAL
Intervention: Quit preparation module
Number of subjects: 2140
Study: 27468229

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed clinic (PMC)
Number of subjects: 244
Study: 23271039

Group type: EXPERIMENTAL
Intervention: Preoperative home exercise program (6-week duration)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no preoperative exercise program)
Number of subjects: 122
Study: 22803422

Group type: EXPERIMENTAL
Intervention: Acupoint heat-sensitization moxibustion (Group A), once daily for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Changtai Oral Liquid (Group B), 10 mL three times daily for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupoint heat-sensitization moxibustion (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Changtai Oral Liquid (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study: 20234040

Group type: EXPERIMENTAL
Intervention: Integrated care (n=66)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care (n=68)
Number of subjects: 134
Study: 17405808

Group type: EXPERIMENTAL
Intervention: Tai chi (TC)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Wellness education (WE)
Number of subjects: 269
Study: 15825977

Group type: EXPERIMENTAL
Intervention: Translated consent form developed by Navajo interpreters and a language consultant; duration of use: four months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard research consent form (not translated); duration of use: not specified.
Number of subjects: 0
Study: 12121581

Group type: EXPERIMENTAL
Intervention: Cranberry tablets (taken twice daily)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cranberry juice (250 ml three times daily)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (juice + tablets)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cranberry tablets
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cranberry tablets vs. cranberry juice
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both cranberry juice and cranberry tablets
Number of subjects: 150
Study: 9707877

Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.25 mg/kg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 76
Study: 7899366

Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg once-a-week (group A: n = 185)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Pefloxacin 400 mg once-a-month (group B: n = 176)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg once-a-week (group A)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Pefloxacin 400 mg once-a-month (group B)
Number of subjects: 361
Study: 2526830

Group type: EXPERIMENTAL
Intervention: Combined intravenous and intracoronary streptokinase without immediate coronary angioplasty (Group I)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Combined intravenous and intracoronary streptokinase with immediate coronary angioplasty (Group II)
Number of subjects: 206
Study: 20918

Group type: EXPERIMENTAL
Intervention: Clobazam (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31033995

Group type: COMPARATOR
Intervention: Psychological symptoms
Number of subjects: 351

Group type: COMPARATOR
Intervention: Anxiety symptoms
Number of subjects: 351

Group type: COMPARATOR
Intervention: Vasomotor symptoms
Number of subjects: 351

Group type: COMPARATOR
Intervention: Depression symptoms
Number of subjects: 351

Group type: COMPARATOR
Intervention: Somatic symptoms
Number of subjects: 351

Group type: COMPARATOR
Intervention: Loss of interest in sex symptoms
Number of subjects: 351

Group type: COMPARATOR
Intervention: Menopausal symptoms
Number of subjects: 351
Study: 28501062

Group type: EXPERIMENTAL
Intervention: Systemic Propolis as an adjuvant to nonsurgical periodontal treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsurgical periodontal treatment
Number of subjects: 0
Study: 26153173

Group type: EXPERIMENTAL
Intervention: 40 mg propranolol, 2 hours before surgery
Number of subjects: 122

Group type: COMPARATOR
Intervention: Combination of 15 mg ketamine and 50 µg fentanyl, 5 min before surgery
Number of subjects: 122
Study: 23569136

Group type: EXPERIMENTAL
Intervention: QuickOpt® optimization (n = 20)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Echocardiography optimization (n = 24)
Number of subjects: 44
Study: 20980491

Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acids intake
Number of subjects: 36328

Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 36328
Study: 19349560

Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 16368752

Group type: EXPERIMENTAL
Intervention: GH treatment (2 IU/m2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23
Study: 15217320

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 152438

Group type: COMPARATOR
Intervention: No BCG vaccination (control)
Number of subjects: 152438
Study: 11080323

Group type: EXPERIMENTAL
Intervention: AeroVent
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: OptiVent
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ACE
Number of subjects: 3

Group type: COMPARATOR
Intervention: Heated-wire ventilator circuit
Number of subjects: 3
Study: 9032099

Group type: EXPERIMENTAL
Intervention: Troglitazone 800 mg q.d.
Number of subjects: 154

Group type: COMPARATOR
Intervention: Glyburide titrated to achieve glycemic control
Number of subjects: 154
Study: 8510088

Group type: EXPERIMENTAL
Intervention: rilmenidine (RIL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCT)
Number of subjects: 20
Study: 2952140

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: CT-guided needle biopsy
Number of subjects: 177
Study: 31398258

Group type: EXPERIMENTAL
Intervention: Online decision aid (DA) in addition to standard counselling
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard counselling only
Number of subjects: 59
Study: 29284735

Group type: EXPERIMENTAL
Intervention: Contact Aspiration (CA)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Stent Retriever (SR)
Number of subjects: 79
Study: 26966970

Group type: EXPERIMENTAL
Intervention: Cognitive patient education
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 216
Study: 25220724

Group type: EXPERIMENTAL
Intervention: Immune investigation including complement function, immunoglobulins with subclasses and cellular immunity.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Immune investigation in children with severe rAOM.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Immune investigation in children without severe rAOM.
Number of subjects: 109
Study: 22711185

Group type: EXPERIMENTAL
Intervention: 5 g of EMLA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac suppository
Number of subjects: 90

Group type: COMPARATOR
Intervention: 5 g of petrolatum ointment
Number of subjects: 90
Study: 20492038

Group type: EXPERIMENTAL
Intervention: Music programme during lunchtime
Number of subjects: 41
Study: 17276176

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 100
Study: 15030456

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 3 g daily from engraftment to day 84
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intravenous ganciclovir 5 mg/kg three times weekly from engraftment to day 84
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 58
Study: 11473677

Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroids (CS)
Number of subjects: 58
Study: 9433395

Group type: EXPERIMENTAL
Intervention: Urinary or recombinant human follicle stimulating hormone (FSH) treatment
Number of subjects: 0
Study: 8495690

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet (CHO) for 3 days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Carbohydrate deficient, protein/fat rich diet (F) for 3 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal unrestricted diet of western type (N)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ergometer cycle endurance test
Number of subjects: 6
Study: 3325531

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 20
Study: 29985230

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No tranexamic acid (No‐TXA)
Number of subjects: 93
Study: 26590950

Group type: EXPERIMENTAL
Intervention: Extended-release-plus-immediate-release bilayer tablet (Test)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gastro-resistant delayed-release tablet (Reference)
Number of subjects: 16
Study: 24980811

Group type: EXPERIMENTAL
Intervention: Moxifloxacin-based triple therapy (MML): moxifloxacin 400 mg/day, metronidazole 500 mg b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential treatment (AL-CML): amoxicillin 1 g b.i.d. and lansoprazole 30 mg b.i.d. for the first 5 days, followed by clarithromycin 500 mg b.i.d., metronidazole 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for the second 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard treatment (CAL): amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for 14 days
Number of subjects: 0
Study: 21999231

Group type: EXPERIMENTAL
Intervention: CHO‐rFVIIa (90 μg/kg for healthy subjects; 270 μg/kg for patients)
Number of subjects: 2

Group type: COMPARATOR
Intervention: BHK‐rFVIIa (90 μg/kg for healthy subjects; 270 μg/kg for patients)
Number of subjects: 2
Study: 20233687

Group type: EXPERIMENTAL
Intervention: Simulated competition
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control laboratory conditions (non-competition)
Number of subjects: 14
Study: 18672762

Group type: EXPERIMENTAL
Intervention: Compound Paeonol Dripping Pill (CPDP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional Western therapy (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tongxinluo (Group C)
Number of subjects: 90
Study: 16896051

Group type: EXPERIMENTAL
Intervention: Vitamin/mineral combination (factor A: retinol and zinc; factor B: riboflavin and niacin; factor C: ascorbic acid and molybdenum; factor D: beta-carotene, alpha-tocopherol, and selenium)
Number of subjects: 29584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29584
Study: 12795457

Group type: EXPERIMENTAL
Intervention: Omeprazole + Clarithromycin (OC) for 2 weeks
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Omeprazole + Amoxicillin + Clarithromycin (OAC-L) for 1 week
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Omeprazole + Amoxicillin + Clarithromycin (OAC-H) for 1 week
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Omeprazole + Metronidazole + Clarithromycin (OMC) for 1 week
Number of subjects: 240
Study: 11035891

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol administered 1 day after mifepristone
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol administered 2 days after mifepristone
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol administered 3 days after mifepristone
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Adverse effects (cramping and nausea)
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Unexpected or serious adverse events
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Acceptability of the procedure
Number of subjects: 2295
Study: 8781154

Group type: EXPERIMENTAL
Intervention: Oblique path (n = 32)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nearly right angle path (n = 30)
Number of subjects: 61
Study: 1310096

Group type: EXPERIMENTAL
Intervention: Peridex (chlorhexidine)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Perimed (povidone iodine and hydrogen peroxide)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Listerine Antiseptic (thymol)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 71
Study: 6422811

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea patients
Number of subjects: 5

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Load detection threshold
Number of subjects: 5
Study: 30737891

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 884

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 884